Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

MLA

Yang X, et al. “Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.” Journal of Hepatocellular Carcinoma, vol. ume 10, Feb. 2023, pp. 303–13. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.b98e7a79ff3046fe973df80927c84fe8&authtype=sso&custid=ns315887.

APA

Yang X, Deng H, Sun Y, Zhang Y, Lu Y, Xu G, & Huang X. (2023). Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma, ume 10, 303–313.

Chicago

Yang X, Deng H, Sun Y, Zhang Y, Lu Y, Xu G, and Huang X. 2023. “Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.” Journal of Hepatocellular Carcinoma ume 10 (February): 303–13. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.b98e7a79ff3046fe973df80927c84fe8&authtype=sso&custid=ns315887.